

# Netherlands

## Recent and planned developments in pharmaceutical policies 2025

### CHANGES IN PRICING

### CHANGES IN REIMBURSEMENT

There have been no recent changes in the pricing or reimbursement of medicines in the Netherlands

### OTHER CHANGES

- The Netherlands is planning to update the pricing and reimbursement process
- The proposed plan is to use horizon scanning as a basis for the P&R process:
  - Early awareness of new developments and awareness of lack of development
  - A triage model for deciding on the route of reimbursement in which important stakeholders come together to discuss whether medicines need to be assessed, what assessment pathway they should follow (e.g. rapid review vs full HTA), and the flagging of potential issues for HTA and negotiations
- The Netherlands is also looking into the pricing of medicines and how to deal with high volume high expenditure products, high uncertainty, evergreening.
- The Netherlands is supporting IHSI in exploring a HS database for MedTech

### SPECIAL TOPIC:

#### Current advances in HTA

(for EU Member States: Implications from EU-HTA Regulation)

- In the Netherlands for outpatient medicines a HTA is required and for inpatient only if it meets certain budgetary requirements (above a threshold)
- The HTAR necessitates earlier engagement between stakeholders to arrive at a PICO – in the Netherlands a special form has been developed between the HTA body and the umbrella organisation of the medical specialists. This will be distributed to the relevant physician associations for filling out the PICO.
- The Health Care Institute will then use this input for preparing the documentation needed for the joint assessment.
- Challenges will likely be to obtain everything in a timely manner and to have agreement on the PICO nationally.